Table 1.
Summary of cited meta-analyses and randomized trials for breast cancer and cervical cancer.
| Reference | Year | Entity | Study type | Treatment arms | RT/CT schedule | P # | HT frequency | Outcome |
|---|---|---|---|---|---|---|---|---|
| Breast cancer | ||||||||
| Vernon et al. (60) | 1995 | Inoperable primary/recurrent breast cancer | MA (5 r trials) | RTHT | Various: effective RT dose 39.8–60 Gy | 171 | mostly 1x/w | CR 59%, |
| RT | 135 | - | 41%, OR 2.3, p < 0,001 | |||||
| Datta et al. (79)a | 2016 | Locoregional recurrence | MA (24 1a.s.) 8 (5 r 2a.s.) | RTHT | Various: 24–60 à 1.8–4 Gy | 1,483 | 1–5x/w | Single arm: CR 63.4% |
| m: 38.2 | 309 | (m: 2) | Two arm: CR 60.2% | |||||
| RT | 318 | – | CR: 38.1%, OR 2.6, p < 0.001 | |||||
| reRTHTb | m: 36.7 à m: 2.7 Gyb | 779b | 1–5x/wb | CR 66.4%b | ||||
| Cervical cancer | ||||||||
| Lutgens et al. (82) | 2010 | Locally advanced cervix carcinoma | Cochrane MA: 6 r 2a.s. | RTHT | Various concepts: EBRT (40–70 Gy) ±BT (16–50 Gy) |
135 | 1–3x/w | CR HR 0.56, p < 0.001 |
| LR HR 0.48, p < 0.001 | ||||||||
| OS HR 0.67, p < 0.05 | ||||||||
| RT | 132 | – | ||||||
| Datta et al. (84) | 2016 | Locally advanced cervix carcinoma | Network MA: 6 r 2a.s. | RTHT | Various concepts: EBRT (40–70 Gy) ±BT (16–60 Gy) |
170 | 1–3x/w | CR: vs. HT: OR 2.85, s |
| RTCT | +Cisplatin | 281 | – | |||||
| RTHTCT | +Cisplatin | 231 | 2x/w | CR: vs. HT: OR 4.52, s vs. HTCT: OR 2.91, s | ||||
| PA: vs. RT: OR 5.57, s vs. CTRT: OR 2.65, s | ||||||||
| RT | 125 | – | ||||||
| Lutgens et al. (86) | 2016 | Locally advanced cervix carcinoma | r pIII | RTCT | EBRT 50 Gy + BT 21/29 Gy +Cisplatin |
43 | – | EFS: HR 1.15, ns |
| OS: HR 1.04, ns | ||||||||
| PRFS: HR 0.94, ns | ||||||||
| RTHT | 44 | 1x/w | ||||||
RT, CT, and HT schemes, p-value or significance status (s/ns) are described as mentioned in the original publications.
a.s., arm study; BT, brachytherapy; CT, chemotherapy; CR, complete response; EFS, event-free survival; HR, hazard ratio; HT, hyperthermia; m, mean; ns, not significant; LR, local recurrence; MA, meta-analysis; OS, overall survival; OR, odds ratio; PRFS, pelvic recurrent-free survival; P #, patient number; p, phase; PA, patients alive; w, week; r, randomized; RT, radiotherapy; s, significant; RTHT, thermoradiotherapy; RTCT, chemoradiotherapy; EBRT, external beam therapy; à, with a single dose of; x/w, times per week.
aIncluding 4 two-arm studies reported in the study by Vernon et al.
bSubgroup analysis.